School of Life Sciences, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea.
Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea.
Sci Transl Med. 2018 Oct 10;10(462). doi: 10.1126/scitranslmed.aam7486.
Developing and mature chondrocytes constantly interact with and remodel the surrounding extracellular matrix (ECM). Recent research indicates that integrin-ECM interaction is differentially regulated during cartilage formation (chondrogenesis). Integrin signaling is also a key source of the catabolic reactions responsible for joint destruction in both rheumatoid arthritis and osteoarthritis. However, we do not understand how chondrocytes dynamically regulate integrin signaling in such an ECM-rich environment. Here, we found that developing chondrocytes express integrin-β-like 1 () at specific stages, inhibiting integrin signaling and promoting chondrogenesis. Unlike cytosolic integrin inhibitors, ITGBL1 is secreted and physically interacts with integrins to down-regulate activity. We observed that expression was strongly reduced in the damaged articular cartilage of patients with osteoarthritis (OA). Ectopic expression of protected joint cartilage against OA development in the destabilization of the medial meniscus-induced OA mouse model. Our results reveal ITGBL1 signaling as an underlying mechanism of protection against destructive cartilage disorders and suggest the potential therapeutic utility of targeting ITGBL1 to modulate integrin signaling in human disease.
不断发育成熟的软骨细胞与周围的细胞外基质(ECM)不断相互作用并重塑。最近的研究表明,整合素-细胞外基质的相互作用在软骨形成(软骨发生)过程中受到差异调控。整合素信号也是导致类风湿关节炎和骨关节炎关节破坏的分解代谢反应的关键来源。然而,我们并不清楚软骨细胞在如此富含细胞外基质的环境中如何动态调节整合素信号。在这里,我们发现发育中的软骨细胞在特定阶段表达整合素-β样 1(ITGBL1),抑制整合素信号并促进软骨形成。与胞质整合素抑制剂不同,ITGBL1 是分泌的,并与整合素发生物理相互作用以下调其活性。我们观察到,OA 患者关节软骨损伤部位的 表达明显降低。在内侧半月板不稳定诱导的 OA 小鼠模型中,异位表达 可保护关节软骨免受 OA 发展的影响。我们的研究结果揭示了 ITGBL1 信号是防止破坏性软骨疾病的潜在机制,并表明靶向 ITGBL1 以调节人类疾病中的整合素信号具有潜在的治疗用途。
Sci Transl Med. 2018-10-10
Ann Rheum Dis. 2014-3-20
Matrix Biol. 2014-10
Arthritis Rheumatol. 2014-5
Stem Cell Res Ther. 2025-8-29
Adv Biomed Res. 2025-7-21
Front Bioeng Biotechnol. 2025-8-8
Exp Mol Med. 2025-3
Int J Mol Sci. 2024-7-30